Ma Chun-wai Delivers Strong First Half Results After Six Months at Hin Sang Group
AM730 · 2 SOURCESabout 4 hours ago4 MIN

Summary
Hin Sang Group (衍生集團) announced on November 17, 2026 a positive profit warning for the first half of fiscal year 2026, marking a significant turnaround under new leadership. Executive Director Ma Chun-wai, who took the helm as Vice Chairman and Co-Chief Executive in May 2026, delivered impressive results just six months into his tenure, with the company reporting growth across key financial metrics including revenue, gross profit, and gross margin while simultaneously narrowing its net loss by more than half compared to the same period last year.
Key Points
- Ma Chun-wai assumed the role of Executive Director, Vice Chairman, and Co-CEO of Hin Sang Group on May 1, 2026
- Revenue for the six months ending September 30, 2026 grew 10.3% year-on-year to approximately 55 million yuan
- Gross profit increased 15.4% to approximately 39.3 million yuan, with gross margin rising from 68.2% to 71.4%
- Consolidated net loss narrowed by approximately 50.3% compared to the same period last year
- Ma credited the team's efforts for the results, stating that leading group development and management is his responsibility
Why It Matters
The positive earnings surprise demonstrates that Ma Chun-wai's reform initiatives—including product R&D acceleration, market strategy adjustments, and operational workflow improvements—are translating into tangible financial gains . Market observers will be closely monitoring whether these early gains can be sustained and expanded in the coming quarters as Hin Sang Group navigates the competitive health product sector.
The positive earnings surprise demonstrates that Ma Chun-wai's reform initiatives—including product R&D acceleration, market strategy adjustments, and operational workflow improvements—are translating into tangible financial gains . Market observers will be closely monitoring whether these early gains can be sustained and expanded in the coming quarters as Hin Sang Group navigates the competitive health product sector.